International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia

[1]  K. Mertens,et al.  A one-year survey of candidemia in Belgium in 2002 , 2004, Epidemiology and Infection.

[2]  J. Lipton,et al.  Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  M. Diaz,et al.  Candidemia in a Brazilian tertiary care hospital: species distribution and antifungal susceptibility patterns. , 2004, Revista do Instituto de Medicina Tropical de Sao Paulo.

[4]  E. Roilides,et al.  Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[5]  K. Pettengell,et al.  Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent , 2004, Alimentary pharmacology & therapeutics.

[6]  M. Pfaller,et al.  Geographic Variation in the Susceptibilities of Invasive Isolates of Candida glabrata to Seven Systemically Active Antifungal Agents: a Global Assessment from the ARTEMIS Antifungal Surveillance Program Conducted in 2001 and 2002 , 2004, Journal of Clinical Microbiology.

[7]  H. Yamaguchi,et al.  A Multicenter, Open-Label Clinical Study of Micafungin (FK463) in the Treatment of Deep-seated Mycosis in Japan , 2004, Scandinavian journal of infectious diseases.

[8]  Lee H. Harrison,et al.  Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program , 2004, Journal of Clinical Microbiology.

[9]  D. Kontoyiannis,et al.  High-dose fluconazole therapy for cancer patients with solid tumors and candidemia: an observational, noncomparative retrospective study , 2004, Supportive Care in Cancer.

[10]  M. Ghannoum,et al.  Candida biofilms: antifungal resistance and emerging therapeutic options. , 2004, Current opinion in investigational drugs.

[11]  J. Sobel,et al.  Guidelines for treatment of candidiasis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  R. Hobson,et al.  The global epidemiology of invasive Candida infections--is the tide turning? , 2003, The Journal of hospital infection.

[13]  D. Pittet,et al.  Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. , 2003, The Lancet. Infectious diseases.

[14]  B. Kullberg,et al.  Voriconazole Salvage Treatment of Invasive Candidiasis , 2003, European Journal of Clinical Microbiology and Infectious Diseases.

[15]  D. Denning.  Echinocandin antifungal drugs , 2003, The Lancet.

[16]  J. Cleary,et al.  Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States , 2003, Antimicrobial Agents and Chemotherapy.

[17]  W. Powderly,et al.  A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  V. Anttila,et al.  Candidemia in Finland, 1995–1999 , 2003, Emerging infectious diseases.

[19]  N. Wiederhold,et al.  The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy , 2003, Expert opinion on investigational drugs.

[20]  J. Rex,et al.  Amphotericin B: time for a new "gold standard". , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  J. Sobel,et al.  A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  J. Perfect,et al.  Voriconazole treatment for less-common, emerging, or refractory fungal infections. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  J. Perfect,et al.  Comparison of caspofungin and amphotericin B for invasive candidiasis. , 2002, The New England journal of medicine.

[24]  D. Pittet,et al.  Secular Trends of Candidemia Over 12 Years in Adult Patients at a Tertiary Care Hospital , 2002, Medicine.

[25]  M. Ghannoum,et al.  Antifungal Susceptibility of Candida Biofilms: Unique Efficacy of Amphotericin B Lipid Formulations and Echinocandins , 2002, Antimicrobial Agents and Chemotherapy.

[26]  E. Anaissie,et al.  Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. , 2002, The New England journal of medicine.

[27]  J. Valgus.  Caspofungin: the first of a new class of antifungal agents. , 2001, Cancer practice.

[28]  J. Neaton,et al.  Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  L. Saiman,et al.  Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  J. Graybill.  Hitting a new target with echinocandins. Why chase something else? , 2001, Current opinion in investigational drugs.

[31]  D. Bates,et al.  Mortality and costs of acute renal failure associated with amphotericin B therapy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  J. Sobel,et al.  Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  Ronald N. Jones,et al.  Bloodstream Infections Due to Candida Species: SENTRY Antimicrobial Surveillance Program in North America and Latin America, 1997-1998 , 2000, Antimicrobial Agents and Chemotherapy.

[34]  T. Patterson.  Role of newer azoles in surgical patients. , 1999, Journal of chemotherapy.

[35]  J. Verhoef,et al.  International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). , 1999, Diagnostic microbiology and infectious disease.

[36]  R. Salomão,et al.  High rate of non-albicans candidemia in Brazilian tertiary care hospitals. , 1999, Diagnostic microbiology and infectious disease.

[37]  L. Saiman,et al.  National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units. , 1999, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[38]  C. Clancy,et al.  Antifungal resistance in non- albicans Candida species. , 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[39]  E. Anaissie,et al.  Predictors of adverse outcome in cancer patients with candidemia. , 1998, The American journal of medicine.

[40]  J. Singer,et al.  Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients , 1997, European Journal of Clinical Microbiology and Infectious Diseases.

[41]  E. Anaissie,et al.  Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[42]  W. Jarvis.  Epidemiology of nosocomial fungal infections, with emphasis on Candida species. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  M. Levenstein,et al.  A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without Neutropenia , 1994 .

[44]  W. Merz.  Candida lusitaniae: frequency of recovery, colonization, infection, and amphotericin B resistance , 1984, Journal of clinical microbiology.

[45]  D. Pappagianis,et al.  Development of Resistance to Amphotericin B in Candida lusitaniae Infecting a Human , 1979, Antimicrobial Agents and Chemotherapy.

[46]  J. Enders,et al.  Infectious Diseases Society of America. , 1969, Antimicrobial agents and chemotherapy.

[47]  M. Pfaller,et al.  Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[48]  N. Gow,et al.  Antifungal agents: mechanisms of action. , 2003, Trends in microbiology.

[49]  D. Denning,et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  J. Sobel,et al.  Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  J. Rex,et al.  A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. , 1994, The New England journal of medicine.